Ganglioside GM2 activator (GM2A) (GM2A)

The Ganglioside GM2 activator (GM2A) is a small, essential lysosomal protein that functions as a lipid-binding cofactor for the degradation of GM2 gangliosides [1]. It acts by extracting GM2 molecules from the lysosomal membrane and presenting them to the enzyme beta-hexosaminidase A, which is otherwise unable to access its lipid substrate in the membrane environment [4]. This interaction is vital for normal lipid metabolism within the cell, particularly in the central nervous system where gangliosides are abundant [1, 2]. Mutations in the GM2A gene lead to the AB variant of GM2-gangliosidosis, a severe lysosomal storage disease that mimics the clinical presentation of Tay-Sachs disease but occurs despite normal levels of hexosaminidase enzymes [3, 5]. As a therapeutic target, GM2A is primarily approached through strategies like gene therapy or recombinant protein replacement to restore its functional activity in deficient patients [2]. Currently, there are no FDA-approved drugs that directly interact with or modulate GM2A, though substrate reduction therapies are used to manage the broader class of gangliosidoses [5]. A major hurdle in developing GM2A-targeted therapies is the requirement for effective delivery to the brain, as the protein must cross the blood-brain barrier to mitigate neurodegeneration [5].

Other names

GM2-APSAP-3Sphingolipid activator protein 3Cerebroside sulfate activator proteinGM2 ganglioside activator

Acts as a lipid-binding cofactor that extracts GM2 gangliosides from lysosomal membranes and presents them to beta-hexosaminidase A for hydrolysis.